AC
BMY.RT

Athos Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Athos Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-635,113
Closed -$438K – 170
2020
Q4 		$438K Buy
635,113
+456,730
+256% +$973K 0.12% 57
2020
Q3 		$401K Buy
178,383
+130,100
+269% +$372K 0.19% 49
2020
Q2 		$173K Sell
48,283
-221,800
-82% -$800K 0.12% 21
2020
Q1 		$1.03M Sell
270,083
-222,214
-45% -$732K 0.71% 15
2019
Q4 		$1.48M Buy
+492,297
New +$1.28M 1.48% 14

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Athos Capital's BMY.RT Position: Q1 2021 in Review

Athos Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 635,113 shares — an estimated $438K sold.

Athos Capital first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1.48M in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Athos Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Athos Capital sold 635,113 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $438K.
  • Athos Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Athos Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.48M in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Athos Capital's 13F filing for Q1 2021, filed 14 May 2021.